/ANRO

Alto Neuroscience Inc

ANRO

$32.00USD↑+1.01%+0.32 today

MARKET CAP

1.3B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$31 – $33

52W RANGE

$4

$37

AI Summary

Stalk

Sell NowMedium

ANRO has decisively broken below short-term EMAs and a prior support cluster on strong volume, confirming continued medium-term bearish control. Short-term momentum is down with price trading below the 9- and 20-day EMAs and RSI trending lower, favoring selling into any rebounds near the broken EMA and support zone. The longer-term uptrend remains intact with price above the 200-day SMA, limiting bearish conviction and signaling that rallies may provide optimal entry points for further selling.

↑Stock gained 9.2% over past two weeks, signaling strong momentum factors.
↑“Moderate Buy” consensus with $36.63 target implies 25.8% upside.
↓EPS expected to fall from ($3.14) to ($3.56), indicating financial strain.

Full analysis →

Buying

3

institutions

Selling

7

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
BI Blackrock, Inc. Q2 2026	BUY	2.12 M	55.97 M	+1.45 M	+273.8%	0.00%
PA Perceptive Advisors LLC Q2 2026	SELL	1.61 M	42.49 M	+-2.41 M	-53.0%	0.64%
MM Millennium Management LLC Q2 2026	SELL	558.32 K	14.73 M	+-263.66 K	-20.3%	0.01%
PA Point72 Asset Management, L.P. Q2 2026	SELL	502.95 K	13.27 M	+-137.00	+17.4%	0.02%
EP Eversept Partners, LP Q2 2026	BUY	128.29 K	3.39 M	+3.12 K	+20.3%	0.18%
RT Renaissance Technologies LLC Q2 2026	SELL	71.40 K	1.88 M	+-32.10 K	-19.0%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	15.10 K	398.49 K	+-16.00 K	-43.0%	0.00%
JC Jpmorgan Chase & Co Q2 2026	BUY	10.90 K	306.07 K	+10.86 K	+33205.2%	0.00%
BH Brevan Howard Capital Management LP Q2 2026	SELL	0.00	0.00	+-38.78 K	-100.0%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	0.00	0.00	+-32.11 K	-100.0%	0.00%